IgG4相关性自身免疫性胰腺炎治疗中免疫抑制剂的应用

张盼盼; 张文

doi:10.3969/j.issn.1001-5256.2018.08.005

IgG4相关性自身免疫性胰腺炎治疗中免疫抑制剂的应用

DOI: 10.3969/j.issn.1001-5256.2018.08.005

张盼盼,
张文

中国医学科学院北京协和医院风湿免疫科

基金项目:

中国医学科学院医学与健康科技创新工程项目(2017-12M-3-001)；国家重点研发计划(2016YFC0901500)；

详细信息

中图分类号: R576
计量
- 文章访问数: 2217
- HTML全文浏览量: 12
- PDF下载量: 427
- 被引次数: 0
出版历程
- 收稿日期: 2018-04-17
- 出版日期: 2018-08-20

Application of immunosuppressant in IgG4-related autoimmune pancreatitis

Department of Rheumatology & Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Science

Research funding:

摘要

摘要: 1型自身免疫性胰腺炎即IgG4相关性自身免疫性胰腺炎目前治疗的首选药物是糖皮质激素。免疫抑制剂与糖皮质激素联合治疗有助于激素减量,并维持疾病的长期缓解。目前对于IgG4相关性疾病的免疫抑制剂治疗,缺乏循证级别较高的前瞻性研究,国际和国内尚无统一规范,主要借鉴其他自身免疫病的经验。介绍了传统药物包括硫唑嘌呤、吗替麦考酚、环磷酰胺、甲氨蝶呤、来氟米特、环孢霉素等,以及生物治疗如靶向B淋巴细胞的利妥昔单抗在该病治疗中的应用情况。
- 胰腺炎 /
- 自身免疫疾病 /
- 免疫球蛋白G /
- 免疫抑制剂
Abstract: At present, glucocorticoids are the first-line drugs for the treatment of type 1 autoimmune pancreatitis, which is also known as IgG4-related autoimmune pancreatitis. Combined treatment with immunosuppressant and glucocorticoids helps to reduce the dose of glucocorticoids and maintain long-term remission. There are no high-quality evidence-based prospective studies of immunosuppressant in the treatment of IgG4-related disease. No uniform standards have been developed in China and the rest of the world, and the treatment of this disease mainly draws experience from other autoimmune diseases. This article introduces the application of conventional drugs ( including azathioprine, mycophenolate mofetil, cyclophosphamide, methotrexate, leflunomide, and cyclosporine) and biological therapy ( for example, rituximab targeting B lymphocytes) in the treatment of autoimmune pancreatitis.
- pancreatitis /
- autoimmune diseases /
- immunoglobulin G /
- immunosuppressive agents

HTML全文

参考文献(45)

[1]SUZUKI D, SHIMIZU K, TOKUSHIGE K.Relative rise of serum Ig G4 levels after steroid therapy for autoimmune pancreatitis predicts the likelihood of relapse[J].Pancreas, 2018, 47 (4) :412-417.

[2]LEE HW, MOON SH, KIM MH, et al.Relapse rate and predictors of relapse in a large single center cohort of type 1 autoimmune pancreatitis:Long-term follow-up results after steroid therapy with short-duration maintenance treatment[J].J Gastroenterol, 2018.[Epub ahead of print]

[3]HUBERS LM, VOS H, SCHUURMAN AR, et al.Annexin A11 is targeted by Ig G4 and Ig G1 autoantibodies in Ig G4-related disease[J].Gut, 2018, 67 (4) :728-735.

[4]OKAZAKI K, CHARI ST, FRULLONI L, et al.International consensus for the treatment of autoimmune pancreatitis[J].Pancreatology, 2017, 17 (1) :1-6.

[5]KUBOTA K, KAMISAWA T, OKAZAKI K, et al.Low-dose maintenance steroid treatment could reduce the relapse rate in patients with type 1 autoimmune pancreatitis:A long-term Japanese multicenter analysis of 510 patients[J].J Gastroenterol, 2017, 52 (8) :955-964.

[6]KAMISAWA T, SHIMOSEGAWA T, OKAZAKI K, et al.Standard steroid treatment for autoimmune pancreatitis[J].Gut, 2009, 58 (11) :1504-1507.

[7]KHOSROSHAHI A, WALLACE ZS, CROWE JL, et al.International consensus guidance statement on themanagement and treatment of Ig G4-related disease[J].Arthritis Rheumatol, 2015, 67 (7) :1688-1699.

[8]WANG L, ZHANG P, WANG M, et al.Failure of remission induction by glucocorticoids alone or in combination with immunosuppressive agents in Ig G4-related disease:A prospective study of 215 patients[J].Arthritis Res Ther, 2018, 20 (1) :65.

[9]BRITO-ZERON P, KOSTOV B, BOSCH X, et al.Therapeutic approach to Ig G4-related disease:A systematic review[J].Medicine, 2016, 95 (26) :e4002.

[10] ZHANG PP, ZHANG W.Clinical, imaging, and pathological features of organ injuries in Ig G4-related diseases[J].Chin J Intern Med, 2016, 55 (8) :657-661. (in Chinese) 张盼盼, 张文.Ig G4相关性疾病脏器损伤的临床特点、影像学及病理特征[J].中华内科杂志, 2016, 55 (8) :657-661.

[11]BRITO-ZERON P, BOSCH X, RAMOS-CASALS M, et al.Ig G4-related disease:Advances in the diagnosis and treatment[J].Best Pract Res Clin Rheumatol, 2016, 30 (2) :261-278.

[12]AKIYAMA M, TAKEUCHI T.Ig G4-related disease:Beyond glucocorticoids[J].Drugs&Aging, 2018.[Epub ahead of print]

[13]SHEN RF, ZENG FD, SHI SJ.Research advances in pharmacological action and clinical application of azathioprine[J].China Pharmacist, 2013, 16 (9) :1409-1412. (in Chinese) 沈如飞, 曾繁典, 师少军.硫唑嘌呤的药理作用和临床应用研究进展[J].中国药师, 2013, 16 (9) :1409-1412.

[14]BOSCO JJ, SUAN D, VARIKATT W, et al.Extra-pancreatic manifestations of Ig G4-related systemic disease:A single-centre experience of treatment with combined immunosuppression[J].Intern Med J, 2013, 43 (4) :417-423.

[15]FRULLONI L, de PRETIS N, AMODIO A.Maintenance therapy in autoimmune pancreatitis:A weak light into the darkness[J].Ann Transl Med, 2017, 5 (17) :367.

[16]de PRETIS N, AMODIO A, BERNARDONI L, et al.Azathioprine maintenance therapy to prevent relapses in autoimmune pancreatitis[J].Clin Transl Gastroenterol, 2017, 8 (4) :e90.

[17]LEE YH, SONG GG.Relative efficacy and safety of tacrolimus, mycophenolate mofetil, and cyclophosphamide as induction therapy for lupus nephritis:A Bayesian network meta-analysis of randomized controlled trials[J].Lupus, 2015, 24 (14) :1520-1528.

[18]ONG LM, HOOI LS, LIM TO, et al.Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis[J].Nephrology (Carlton, Vic) , 2005, 10 (5) :504-510.

[19]HART PA, ZEN Y, CHARI ST.Recent advances in autoimmune pancreatitis[J].Gastroenterology, 2015, 149 (1) :39-51.

[20]MANNION M, CRON RQ.Successful treatment of pediatric Ig G4related systemic disease with mycophenolate mofetil:C``ase report and a review of the pediatric autoimmune pancreatitis literature[J].Pediatr Rheumatol Online J, 2011, 9 (1) :1.

[21]MOSS HE, MEJICO LJ, de la ROZA G, et al.Ig G4-related inflammatory pseudotumor of the central nervous system responsive to mycophenolate mofetil[J].J Neurol Sci, 2012, 318 (1-2) :31-35.

[22]SISTIGU A, VIAUD S, CHAPUT N, et al.Immunomodulatory effects of cyclophosphamide and implementations for vaccine design[J].Semin Immunopathol, 2011, 33 (4) :369-383.

[23]DAN D, FISCHER R, ADLER S, et al.Cyclophosphamide:As bad as its reputation?Long-term single centre experience of cyclophosphamide side effects in the treatment of systemic autoimmune diseases[J].Swiss Med Wkly, 2014, 144:w14030.

[24]TELES KA, MEDEIROS-SOUZA P, LIMA FA, et al.Cyclophosphamide administration routine in autoimmune rheumatic diseases:A review[J].Rev Bras Reumatol Engl Ed, 2017, 57 (6) :596-604.

[25]ZHU LP, CUPPS TR, WHALEN G, et al.Selective effects of cyclophosphamide therapy on activation, proliferation, and differentiation of human B cells[J].J Clin Invest, 1987, 79 (4) :1082-1090.

[26]YUNYUN F, YU C, PANPAN Z, et al.Efficacy of Cyclophosphamide treatment for immunoglobulin G4-related disease with addition of glucocorticoids[J].Sci Rep, 2017, 7 (1) :6195.

[27]DELLA-TORRE E, CAMPOCHIARO C, BOZZOLO EP, et al.Methotrexate for maintenance of remission in Ig G4-related disease[J].Rheumatology, 2015, 54 (10) :1934-1936.

[28]MORRIS RE, HUANG X, CAO W, et al.Leflunomide (HWA486) and its analog suppress T-and B-cell proliferation in vitro, acute rejection, ongoing rejection, and antidonor antibody synthesis in mouse, rat, and cynomolgus monkey transplant recipients as well as arterial intimal thickening after balloon catheter injury[J].Transplant Proc, 1995, 27 (1) :445-447.

[29]WANG Y, LI K, GAO D, et al.Combination therapy of leflunomide and glucocorticoids for the maintenance of remission in patients with Ig G4-related disease:A retrospective study and literature review[J].Intern Med J, 2017, 47 (6) :680-689.

[30]SCHWAIGER T, van den BRANDT C, FITZNER B, et al.Autoimmune pancreatitis in MRL/Mp mice is a T cell-mediated disease responsive to cyclosporine A and rapamycin treatment[J].Gut, 2014, 63 (3) :494-505.

[31]ZHANG YZ, ZHANG CX.Research progress of pharmacological effects and clinical efficacy of tacrolimus[J].Chin Hosp Pharm J, 2016, 36 (3) :241-244. (in Chinese) 张咏赞, 张翠欣.他克莫司药理作用及临床疗效的研究进展[J].中国医院药学杂志, 2016, 36 (3) :241-244.

[32]BUECHTER M, KLEIN CG, KLOETERS C, et al.Tacrolimus as a reasonable alternative in a patient with steroid-dependent and thiopurine-refractory autoimmune pancreatitis with Ig G4-associated cholangitis[J].Z Gastroenterol, 2014, 52 (6) :564-568.

[33]SELEZNIK G, GRAF R.Alternatives to steroids?!Beneficial effects of immunosuppressant drugs in autoimmune pancreatitis[J].Gut, 2014, 63 (3) :376-377.

[34]ZHANG JL, HUANG F.Pharmacological action of hydroxychloroquine and its application in rheumatic diseases[J].Pharm J Chin PLA, 2000, 16 (2) :85-88. (in Chinese) 张江林, 黄烽.羟氯喹的药理作用及在风湿性疾病中的应用[J].解放军药学学报, 2000, 16 (2) :85-88.

[35]MUCKE HA.Iguratimod:A new disease-modifying antirheumatic drug[J].Drugs Today (Barc) , 2012, 48 (9) :577-586.

[36]XIAO W, GUO JP, LI C, et al.Genetic predictors of efficacy and toxicity of iguratimod in patients with rheumatoid arthritis[J].Pharmacogenomics, 2018, 19 (5) :383-392.

[37]MAJUMDER S, MOHAPATRA S, LENNON RJ, et al.Rituximab maintenance therapy reduces rate of relapse of pancreaticobiliary immunoglobulin G4-related disease[J].Clin Gastroenterol Hepatol, 2018.[Epub ahead of print]

[38]WALLACE ZS, MATTOO H, MAHAJAN VS, et al.Predictors of disease relapse in Ig G4-related disease following rituximab[J].Rheumatology, 2016, 55 (6) :1000-1008.

[39]KAMISAWA T, OKAZAKI K.Diagnosis and treatment of Ig G4-related disease[J].Curr Top Microbiol Immunol, 2017, 401:19-33.

[40]CARRUTHERS MN, TOPAZIAN MD, KHOSROSHAHI A, et al.Rituximab for Ig G4-related disease:A prospective, open-label trial[J].Ann Rheum Dis, 2015, 74 (6) :1171-1177.

[41]STONE JH, CARRUTHERS MN, TOPAZIAN MD, et al.Response to:Is rituximab effective for Ig G4-related disease in the long term?Experience of cases treated with rituximab for 4 years'by Yamamoto et al[J].Ann Rheum Dis, 2015, 74 (8) :e47.

[42]PARK DH, KIM M, OH HB, et al.Substitution of aspartic acid at position 57 of the DQβ1 affects relapse of autoimmune pancreatitis[J].Gastroenterology, 2008, 134 (2) :440-446.

[43]KHOSROSHAHI A, STONE JH.Treatment approaches to Ig G4-related systemic disease[J].Curr Opin Rheumatol, 2011, 23 (1) :67-71.

[44]SATO Y, KOJIMA M, TAKATA K, et al.Multicentric Castleman's disease with abundant Ig G4-positive cells:A clinical and pathological analysis of six cases[J].J Clin Pathol, 2010, 63 (12) :1084-1089.

[45]YAMAMOTO M.New strategies for the treatment of Ig G4-related disease[J].Nihon Rinsho Meneki Gakkai Kaishi, 2016, 39 (6) :485-490.

施引文献

资源附件(0)

访问统计